The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023;59:1136 DOI: 10.3390/medicina59061136
T2D and NAFLD/NASH share common causal pathways. As a class of glucose-lowering agents with well-established cardiovascular benefits, SGLT2i have been studied for effects on steatosis and fibrosis in patients with NAFLD or NASH. A systematic review was conducted to examine the efficacy of SGLT2i on NAFLD/NASH in patients who also had T2D.
In total, 21 articles were included in the analysis, with dapagliflozin and empagliflozin most commonly studied. There was considerable variability in study duration, sample size and endpoints. Overall, SGLT2i treatment resulted in improvements in non-invasive markers of steatosis in patients with NAFLD/NASH and T2D, with some evidence of reduced fibrosis in a small number of studies.
Keywords:
